1. Stem Cell/Wnt
  2. Wnt

Wnt

The Wnt signaling pathways are a group of signal transduction pathways made of proteins that pass signals from outside of a cell through cell surface receptors to the inside of the cell. Three Wnt signaling pathways have been characterized: the canonical Wnt pathway, the noncanonical planar cell polarity pathway, and the noncanonical Wnt/calcium pathway. All three Wnt signaling pathways are activated by the binding of a Wnt-protein ligand to a Frizzled family receptor, which passes the biological signal to the protein Dishevelled inside the cell. The canonical Wnt pathway leads to regulation of gene transcription, the noncanonical planar cell polarity pathway regulates the cytoskeleton that is responsible for the shape of the cell, and the noncanonical Wnt/calcium pathway regulates calcium inside the cell. The clinical importance of Wnt signaling pathway has been demonstrated by mutations that lead to a variety of diseases, including breast and prostate cancer, glioblastoma, type II diabetes.

Wnt Related Products (153):

Cat. No. Product Name Effect Purity
  • HY-10182
    Laduviglusib Activator
    Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy[1][2][3].
  • HY-13912
    IWP-2 Inhibitor 99.51%
    IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation. IWP-2 is also an ATP-competitive CK1δ inhibitor with an IC50 of 40 nM for the gatekeeper mutant M82FCK1δ[1][2].
  • HY-12238
    IWR-1 Inhibitor 99.49%
    IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway.
  • HY-N0150
    Monensin sodium Inhibitor
    Monensin (Monensin A) sodium, an orally active antibiotic, is an ionophore that mediates Na+/H+ exchange. Monensin sodium is a potent Wnt signaling inhibitor. Monensin sodium causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin sodium can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects[1][2][3][4].
  • HY-15659
    Wnt-C59 Inhibitor 99.86%
    Wnt-C59 (C59) is a highly potent and oral porcupine (PORCN) inhibitor with an IC50 of 74 pM.
  • HY-160709
    Wnt/β-catenin-IN-2 Inhibitor
    Wnt/β-catenin-IN-2 (Compound 3235-0367) is a Wnt/β-catenin signaling pathway inhibitor, with IC50 and KD values of 7.1 and 2.5 μM, respectively. Wnt/β-catenin-IN-2 can be used for the research of cancer[1].
  • HY-E70290
    N-Acetylgalactosaminyltransferase 1 Agonist
    N-Acetylgalactosaminyltransferase 1 (GALNT1) is a glycosyltransferase that initiates mucin-type O-glycosylation by transferring α-GalNAc from UDP-GalNAc to serine (Ser) or threonine (Thr) residues in proteins. Overexpression of N-Acetylgalactosaminyltransferase 1 in gastric cancer promotes the Wnt/β-catenin signaling pathway through abnormal O-glycosylation of CD44, thereby enhancing malignancy. N-Acetylgalactosaminyltransferase 1 plays a crucial role in cancer growth and metastasis by modifying O-glycosylation of various glycoproteins, such as mucin (MUC1), osteopontin (OPN), matrix metalloproteinase-14 (MMP14), and integrin α3[1].
  • HY-163513
    AACA Agonist
    AACA is an inhibitor for sclerostin, that binds sclerostin on loop3 region with Kd of 15.4 nM. AACA exhibits anti-osteoporosis activity through Wnt signaling pathway[1].
  • HY-10182C
    Laduviglusib dihydrochloride Activator
    Laduviglusib;CHIR 99021;CHIR99021;CHIR-99021;CT99021;CT 99021;CT-99021
  • HY-P10164
    Pen-N3 Inhibitor
    Pen-N3 is a PDZ peptide. Pen-N3 inhibits Wnt/b-catenin signaling by recognizing dishevelled protein[1].
  • HY-129566
    Withanolide B Activator
    Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects[1][2][3].
  • HY-P9974
    Vantictumab Inhibitor 99.40%
    Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2].
  • HY-153855
    Zamaporvint Inhibitor 99.76%
    Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. Zamaporvint targete membrane-bound o-acyltransferase Porcupine and inhibited Wnt ligand palmitoylation, secretion, and pathway activation. Zamaporvint displays a favorable pharmacokinetic profile and shows potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines. Zamaporvint possesses multiple antitumor mechanisms and can be used in cancer research[1].
  • HY-N0279
    Cardamonin Inhibitor 98.38%
    Cardamonin can be found from cardamom, and target various signaling molecules, transcriptional factors, cytokines and enzymes. Cardamonin can inhibit mTOR, NF-κB, Akt, STAT3, Wnt/β-catenin and COX-2. Cardamonin shows anticancer, anti-inflammatory, antimicrobial and antidiabetic activities[1][2].
  • HY-N7702
    N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide Antagonist 98.05%
    N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp.) N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical Wnt/β‐catenin signaling pathway. N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide can be used for the research of osteoporosis[1].
  • HY-W010995
    2,5-Dimethylcelecoxib Inhibitor 99.57%
    2,5-Dimethylcelecoxib is an analogue of celecoxib (HY-14398) with anticancer activity but without COX-2 inhibitory activity. 2,5-Dimethylcelecoxib exerts its anti-cancer cell proliferation effect by inhibiting the core mechanism of the Wnt/β-catenin signaling pathway. 2,5-Dimethylcelecoxib also inhibits T-cell factor-dependent transcriptional activity and inhibits expression of the Wnt/β-catenin target gene products cyclin D1 and survivin[1].
  • HY-13912G
    IWP-2 (GMP) Inhibitor
    IWP-2 (GMP) is IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation[1].
  • HY-75342
    Methyl vanillate Activator
    Methyl vanillate, one of the ingredients in Oryza sativa Linn., is a Wnt/β-catenin pathway activator[1]. A benzoate ester that is the methyl ester of vanillic acid. It has a role as an antioxidant and a plant metabolite.
  • HY-P5819
    xStAx-VHLL Inhibitor
    xStAx-VHLL is a PROTAC β-catenin degrader that manifests strong inhibition of Wnt signaling and sustains degradation of β-catenin in cancer cells and the intestinal organoids derived from wild-type and APC–/– mice. xStAx-VHLL can be used as a promising anticancer agent[1].
  • HY-119751
    Hematein Inhibitor
    Hematein is a oxidation product of hematoxylin acted as a dye[1]. Hematein is an allosteric casein kinase II inhibitor with an IC50 of 0.74 μM. Hematein inhibits Akt/PKB Ser129 phosphorylation, the Wnt/TCF pathway and increases apoptosis in lung cancer cells[2].